NGS IVD Technology Assessment

Purpose

To asses the state of implementation of Next-Generation Sequencing (NGS) as a potential disruptive technology in the clinical setting and its impact on existing IVD technologies in the U.S.

Process

BBC conducted primary market research with 45 clinical U.S. laboratories to assess drivers and inhibitors, current and future plans of adoption, and remaining unmet needs.

Results

BBC was able to assess the relevance and future use and application of the technology while identifying specific customer needs, commercial opportunities, threats, and specific implications for key stakeholders.